Skip to main content

AHA: Bumetanide Nasal Spray Statistically Bioequivalent to Oral Bumetanide

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 25, 2024.

via HealthDay

MONDAY, Nov. 25, 2024 -- Bumetanide nasal spray (BNS) has statistical bioequivalence to oral bumetanide, according to a research letter published online Nov. 18 in Circulation to coincide with the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Andrew P. Ambrosy, M.D., from the Kaiser Permanente San Francisco Medical Center, and colleagues conducted an open-label, randomized controlled trial in healthy volunteers to compare the bioavailability of BNS to that of an oral tablet and intravenous (IV) bumetanide. Sixty-eight participants were assigned to one of four treatment sequences across five treatment periods, with a 48-hour washout period between treatments.

The researchers found that BNS achieved its primary end point, demonstrating statistical bioequivalence to oral bumetanide for maximum concentration, area under the concentration-time curve 0-t, and area under the concentration-time curve 0-inf. BNS was absorbed more rapidly, with a median time to maximum concentration of 1.0 and 1.5 hours for BNS and the oral formulation, respectively. Twenty-seven percent variability in absorption was seen for the nasal and IV forms compared with >40 percent for the oral form. BNS had comparable pharmacodynamic effects of diuresis and natriuresis to IV and oral bumetanide. Fewer individuals experienced treatment-emergent adverse events after BNS treatment compared with the IV and oral forms (8.8 percent versus 9.1 and 17.9 percent, respectively).

"We were surprised by how fast the nasal spray worked and by how variable the absorption of the oral drug was even in healthy subjects," coauthor Daniel Bensimhon, M.D., of Cone Health in Greensboro, North Carolina, said in a statement.

Several authors disclosed ties to pharmaceutical companies, including Corstasis Therapeutics, which developed and manufactured the BNS tested in the study and funded the study.

Abstract/Full Text

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Sense of Life Purpose Lowers Risk for Cognitive Impairment

THURSDAY, Sept. 4, 2025 -- A sense of purpose in life (PiL) is associated with a lower risk for and later onset of cognitive impairment, according to a study published online in...

Risk for Second Cancer Low for Women Treated for Early, Invasive Breast Cancer

THURSDAY, Sept. 4, 2025 -- The risk for second primary cancers is higher for breast cancer survivors than for women in the general population; however, the risk remains low and is...

Paternal Prepubertal Passive Smoke Exposure Impacts Offspring Lung Function

THURSDAY, Sept. 4, 2025 -- Paternal passive smoke exposure before completing puberty may intergenerationally impair lung function in future generations, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.